Issue link: https://beckershealthcare.uberflip.com/i/1094308
51 GASTROENTEROLOGY "If a practice is in an area where they are competitively sound, [PE investments] will have no effect or a very little effect," Dr. Gagneja said. "In big metroplexes, where the deals have consummated or will happen in the near future, it will be very difficult to survive for small, independent practices." If a practice is well-situated and made investments in quality reporting systems, valued-based care and has planned for future growth, "they probably do not have anything to worry about," Mr. Mitchell said. However, Mr. Mitchell added if payer networks continue to narrow, PE investments could present a compelling case to smaller practices. "PE-backed groups are going to be able to make a very compel- ling case for themselves given the data they will have about clinical outcomes, patient satisfaction and access. Larger groups are able to make significant investments to drive quality and sophistication of care, which could be a huge competitive advantage in the future." An unknown ending e Treaty of Paris ended the American Revolutionary War, with Britain ceding much of its territory in the Americas to the U.S. e exact details on how PE investments will ultimately impact the GI field remains unanswered, but investments are fueling consolidation due to practices wanting security and relevance through scalability. A lack of comparable data on PE deals, even from investment in other healthcare specialties, raises flags on how practices will ben- efit, yet the attractiveness of added resources with little to no impact on the clinical side is a hard proposition for independent practices to turn down. e fight to stay independent is underway, and as it advances, the world will be watching. n FDA approves DNA testing company 23andMe's hereditary CRC test — 4 insights By Eric Oliver T he FDA awarded DNA testing company 23andMe clearance to include risk reports associated with hereditary colorectal cancer in its testing suite. What you should know: 1. 23andMe will soon include information on genetic variants that can influence MUTYH-associated polyposis in its reports. 2. If customers opt-in to the report, 23andMe is providing an education module to help them interpret the results and understand the limitations of the report. 3. Hereditary CRC cases account for about 5 percent of all CRC cases, the company said. 4. Company CEO Anne Wojcicki said, "We are committed to giving people affordable and direct access to important health information that can impact their lives. We believe improved access to genetic testing and health information will help people engage in their own health." n MINI & FULL-SIZE C-ARMS FOR ALL YOUR IMAGING NEEDS. OrthoScan FD Pulse The First & Only Mini C-Arm with Pulsed Fluoroscopy Visit OrthoScan at AAOS! Booth #5046 • Las Vegas, NV March 13 - 15, 2019 orthoscan.com Ziehm Imaging Solo FD Versatile design meets latest flat-panel technology